- Home
- GTEC vs TENX Comparison
GTEC vs TENX Comparison
Compare GTEC & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GTEC
- TENX
- Stock Information
- Founded
- GTEC 2006
- TENX 1967
- Country
- GTEC United States
- TENX United States
- Employees
- GTEC N/A
- TENX N/A
- Industry
- GTEC Industrial Machinery/Components
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- GTEC Industrials
- TENX Health Care
- Exchange
- GTEC Nasdaq
- TENX Nasdaq
- Market Cap
- GTEC 18.2M
- TENX 21.7M
- IPO Year
- GTEC N/A
- TENX N/A
- Fundamental
- Price
- GTEC $1.90
- TENX $6.30
- Analyst Decision
- GTEC
- TENX Strong Buy
- Analyst Count
- GTEC 0
- TENX 3
- Target Price
- GTEC N/A
- TENX $16.00
- AVG Volume (30 Days)
- GTEC 4.7M
- TENX 20.7K
- Earning Date
- GTEC 03-26-2025
- TENX 05-13-2025
- Dividend Yield
- GTEC N/A
- TENX N/A
- EPS Growth
- GTEC N/A
- TENX N/A
- EPS
- GTEC 1.03
- TENX N/A
- Revenue
- GTEC $83,944,661.00
- TENX N/A
- Revenue This Year
- GTEC N/A
- TENX N/A
- Revenue Next Year
- GTEC $1.70
- TENX N/A
- P/E Ratio
- GTEC $1.84
- TENX N/A
- Revenue Growth
- GTEC N/A
- TENX N/A
- 52 Week Low
- GTEC $1.17
- TENX $2.77
- 52 Week High
- GTEC $2.94
- TENX $7.89
- Technical
- Relative Strength Index (RSI)
- GTEC 58.33
- TENX 49.26
- Support Level
- GTEC $1.57
- TENX $6.00
- Resistance Level
- GTEC $2.16
- TENX $6.76
- Average True Range (ATR)
- GTEC 0.17
- TENX 0.40
- MACD
- GTEC 0.10
- TENX 0.02
- Stochastic Oscillator
- GTEC 51.84
- TENX 39.47
About GTEC Greenland Technologies Holding Corporation
Greenland Technologies Holding Corp is a developer of quality solutions in the material handling industry. It is a transmission and drivetrain systems provider for material handling equipment such as forklift trucks for industrial and logistic applications. Geographically, the company has its presence in Domestic and International markets and earns majority of the revenue from Domestic Sales.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.